STOCK TITAN
  1. Home
  2. Sec-filings
  3. KMDA
  4. [6-K] KAMADA LTD Current Report (Foreign Issuer)

Record H1 2026 lifts Kamada (KMDA) to cash dividend

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Kamada Ltd. announced that its Board of Directors declared a cash dividend of $0.17 per share (approximately NIS 0.50), totaling about $9.8 million, on its ordinary shares. The dividend is consistent with the company’s cash dividend policy and follows record-high revenue and profitability for the first six months of 2026.

The dividend will be paid on September 17, 2026, to shareholders of record as of August 27, 2026, with tax withheld under Israeli law. Kamada highlights confidence in its business prospects and liquidity while continuing to invest in commercial growth, business development, and M&A. FIMI Opportunity Funds remains the controlling shareholder with about 38% of outstanding ordinary shares.

Positive

  • Board declared a $0.17 per share cash dividend, totaling about $9.8 million, signaling capital return to shareholders.
  • Company reported record-high revenue and profitability for the first six months of 2026, indicating strong recent operating performance.
  • Management states confidence in business prospects and liquidity while funding both growth initiatives and ongoing dividend payments.

Negative

  • None.

Filing Explained

The August 17 Form 6-K states that it is incorporated by reference into six Form S-8 registration statements.

Dividend per share $0.17 per share Cash dividend declared on ordinary shares
Dividend per share (NIS) approximately NIS 0.50 per share Approximate local-currency equivalent of $0.17 dividend
Total dividend amount approximately $9.8 million Aggregate cash dividend for all ordinary shares
Dividend record date August 27, 2026 Shareholders of record on this date receive the dividend
Dividend payment date September 17, 2026 Scheduled date for cash dividend payment
Controlling shareholder stake approximately 38% of outstanding ordinary shares FIMI Opportunity Funds’ beneficial ownership
Operating plasma collection centers three FDA-approved centers Beaumont, Houston, and San Antonio, Texas
cash dividend policy financial
"The dividend payment is consistent with the Company’s dividend policy"
specialty plasma-derived therapies medical
"a leader in the specialty plasma-derived therapies field"
hyper-immune plasma medical
"increasing demand for hyper-immune plasma"
plasma collection centers technical
"The Company currently owns three FDA-approved operating plasma collection centers"
forward-looking statements regulatory
"This release includes forward-looking statements within the meaning of Section 21E"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What dividend did Kamada (KMDA) declare in August 2026?
Kamada declared a cash dividend of $0.17 per share, or about NIS 0.50, totaling approximately $9.8 million. The payment aligns with the company’s dividend policy and follows record-high revenue and profitability in the first half of 2026.

When is the record date and payment date for Kamada’s August 2026 dividend?
The dividend will be paid on September 17, 2026, to shareholders of record at the close of business on August 27, 2026. Investors holding Kamada shares on the record date will be eligible to receive the declared cash dividend.

How large is Kamada’s total dividend distribution announced in August 2026?
The total dividend distribution is approximately $9.8 million, based on a per-share dividend of $0.17. This cash return reflects management’s confidence in Kamada’s financial position after achieving record-high revenue and profitability in the first half of 2026.

Will there be tax withholding on Kamada’s August 2026 dividend for KMDA shareholders?
Kamada will withhold tax on the dividend in accordance with Israeli tax laws. The company has applied for a ruling regarding withholding for non-Israeli shareholders and plans to announce the main terms of that ruling once obtained.

What did Kamada disclose about its financial performance for the first half of 2026?
Kamada reported record-high revenue and profitability for the first six months of 2026. While specific figures were not detailed here, the company linked this strong performance and solid cash position to its decision to declare the cash dividend.

Who is Kamada’s controlling shareholder and what stake do they hold?
Kamada stated that FIMI Opportunity Funds is its controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. This significant stake gives FIMI substantial influence over the company’s strategic direction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the Month of August 2026

 

Commission File Number 001-35948

 

Kamada Ltd.

(Translation of registrant’s name into English)

 

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

 

 

 

 

 

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

 

1

 

 

The following exhibit is attached:

 

99.1   Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 17, 2026 KAMADA LTD.
   
  By: /s/ Nir Livneh
   

Nir Livneh

Vice President General Counsel and
Corporate Secretary

 

3

 

 

EXHIBIT INDEX

 

EXHIBIT NO.   DESCRIPTION
99.1   Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

 

4

 

Exhibit 99.1

 

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

 

Dividend to be Paid Consistent with the Company’s Cash Dividend Policy

 

REHOVOT, Israel, and HOBOKEN, NJ – August 17, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that its Board of Directors has declared a cash dividend of $0.17 (approximately NIS 0.50) per share on the Company’s ordinary shares (totaling approximately $9.8 million). The cash dividend will be payable on September 17, 2026, to shareholders of record at the close of business on August 27, 2026. The dividend payment is consistent with the Company’s dividend policy.

 

“Based on the Company’s record-high financial results for the first six months of 2026 and our solid cash position, we are pleased to announce a cash dividend to be paid to our shareholders,” said Amir London, Kamada’s Chief Executive Officer. “This dividend payment reinforces our confidence in the Company’s business prospects and liquidity to continue investing in our commercial growth and securing new business development and M&A transactions, while also paying dividend to our shareholders. I would like to thank our shareholders for their continued support and trust in Kamada.”

 

The Company will withhold tax on the dividend in accordance with Israeli tax laws. The Company has applied for a ruling from the Israel Tax Authority in connection with tax withholding to non-Israeli shareholders and will announce the main terms of such ruling once obtained.

 

About Kamada

 

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third-parties pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

 

Cautionary Note Regarding Forward-Looking Statements

 

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) Kamada’s confidence of its business prospects and liquidity, and 2) Kamada’s continued investment in its commercial growth, including securing new business development and M&A transactions, while also paying dividend to its shareholders. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East, and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the effect of imposed tariffs on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada’s ability to leverage new business opportunities and integrate them with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

 

CONTACTS:

 

Chaime Orlev

Chief Financial Officer

IR@kamada.com

 

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

britchie@LifeSciAdvisors.com

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases